Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab Plus Chemotherapy in ESCC
NCT03985670Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2019
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological Complete Response Rate at 2 months. Status: unknown.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03985670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985670.